Glargine 300 IU/ml (Toujeo) in patients with diabetes mellitus type 1 in a real outpatient practice: clinical features of practical use
AbstractWith diabetes mellitus type 1 (DM1), an absolute insulin deficiency is observed in the body due to the destruction of β-cells. Therefore, life-substituting insulin therapy is, to date, the only method for treating patients with this pathology. The leading role in the formation of a stable glycemic profile, first of all, to basal insulin. Despite the obvious advantages of the already existing basal insulin analogs, in many patients with DM1, marked day-to-day differences in glucose levels as well as unpredictable glucose fluctuations within the same day and hypoglycemia are still observed. The article presents a clinical analysis of the use of insulin glargine with a concentration of 300 U/ml (Toujeo) in 70 patients with DM1 in real outpatient practice. The important clinical features and control points for the initiation of Toujeo therapy are described in detail, which allows using a new preparation of basal insulin with maximum efficiency.
Keywords:diabetes mellitus type 1, basal insulin preparations, practical application, clinical features, Lantus, glargine, Toujeo
Endocrinology: News, Opinions, Training. 2017; (3): 51-63. DOI: 10.24411/2304-9529-2017-00031